Medical researchers at the University of Alberta have discovered a promising new therapy for Huntington disease that restores lost motor skills and may delay or stop the progression of the disease based on lab model tests, says the lead researcher. Because the new therapy uses a molecule already being used in clinical trials for other diseases, it could be used in a clinical trial for Huntington disease within the next one to two years. "We didn't expect to see such dramatic changes after administering this therapy, " said Simonetta Sipione, the Principal Investigator "We expected to see improvement, but not complete restoration of motor skills. When we saw this, we were jumping with excitement in the lab. This is very promising and should give hope to those with Huntington disease. I think it's a treatment that deserves to go to clinical trials because it could have huge potential.
The Na-GST-1 antigen, a candidate for the first human hookworm vaccine developed by the Sabin Vaccine Institute (Sabin), has entered a Phase 1 human trial in Brazil, according to Sabin. For the vaccine product development partnership (PDP) headquartered at Sabin, the clinical trial is a considerable achievement. Worldwide, almost 600 million individuals are infected by human hookworm. Sabin's aim is to create a safe, effective and inexpensive vaccine, in order to reduce the worldwide burden of this parasite. The trial is being conducted by a team based at the Oswaldo Cruz Foundation (FIOCRUZ) of the Brazilian Ministry of Health, a member of the Sabin PDP in Brazil, where the prevalence of hookworm infection is high in endemic regions. Peter Hotez, M.D., Ph.D., president of the Sabin Vaccine Institute and director of the Texas Children's Hospital Center for Vaccine Development, and dean of the National School of Tropical Medicine at Baylor College of Medicine, explained: "This vaccine trial is monumental, not just for us, but also for the children living in poverty who bear the burden of hookworm infection.
The pharmaceutical company Ferrer has received approval to start phase III human trials of ozenoxacin, formulated as a topical treatment for infectious skin conditions. In February 2012, participants are expected to enter the multicenter, randomized, placebo controlled, parallel, double-blinded superiority clinical study, which is scheduled to complete in 2013. The study will consist of approximately 465 infants younger than 2 years old, with a clinical diagnosis of non-bullous or bullous impetigo, at around 50 centers in the USA, Germany, Romania, Ukraine, South African and India, subject to completion of additional regulatory approvals. Participants will receive either ozenoxacin 1% cream or placebo. Ozenoxacin belongs to a new generation of non-fluorinated quinolone antibacterial agent.
Pfizer Inc. and Medivation, Inc. announced results from their 'CONCERT' trial today. CONCERT is a Phase 3 trial that evaluated dimebon (latrepirdine), which is used to treat patients with mild-to-moderate Alzheimer's disease. Dimebon is added to ongoing treatment with donepezil HCL tablets. Although the drug was well tolerate by patients, unfortunately Dimebon did not appear to achieve the required results for either of the two tests assigned to the trial : the Alzheimer's Disease Assessment Scale, a cognitive subscale (ADAS-cog), which measures cognitive ability, or the Alzheimer's Disease Cooperative Study, Activities of Daily Living (ADCS-ADL), which measures self care and daily function. David Hung, M.D., president and CEO of Medivation said : "We are disappointed in the CONCERT results and the implications for Alzheimer's disease patients and their caregivers .
An experimental drug for advanced colorectal cancer that available treatments have failed to halt, has shown promise in a clinical trial, says Bayer HealthCare, the company that makes it. The results of the phase III trial show that compared to placebo, regorafenib slowed tumor growth and extended survival. In a statement released yesterday, Bayer announced that the Phase III CORRECT (Colorectal cancer treated with regorafenib or placebo after failure of standard therapy) trial "met its primary endpoint, showing statistically significant improvement in overall survival ... in patients with metastatic colorectal cancer (mCRC) whose disease had progressed after approved standard therapies". The statement goes on to add that the trial also shows that regorafenib showed statistically significant improvement in progression-free survival and improvement in disease control rate in the patients who received the drug compared to those who received placebo.